A novel integrated gene coexpression analysis approach reveals a prognostic three-transcription-factor signature for glioma molecular subtypes

Table 1 Six glioma data sets used in the study

Data sets	Platform	Component of samples	Use
GSE4290	GPL570	157 glioma (AII 7, AIII 19, GBM 77, OII 38, OIII 12, unknown 4), 23 epilepsy	Used for DCEA and DRA analysis
GSE16011	GPL8542	284 glioma (PA 8, AII 13, AIII 16, GBM 159, OII 8, OIII 44, OAII 3, OAIII 25),8 normal adult brain samples	Training set for searching for DRA-based signature
Rembrandt	GPL570	521 gliomas (A 148, GBM 228, O 67, OA 11, unknown 67), 21 epilepsy	Training set for searching for DRA-based signature
Tiantan	Agilent 44 K array	212 glioma (AII 58, AIII 8, GBM 82, OII 18, OIII 10, OAII 21, OAIII 15)	Training set for searching for DRA-based signature
TCGA mRNA-seq	IlluminaHiseq_RNAseq	519 gliomas (AII 38, AIII 84, GBM 160, OII 83, OIII 54, OAII 55, OAIII 45)	Training set for searching for DRA-based signature
GSE4412	GPL96	85 gliomas(A 8,GBM 59,OA 7,O 11)	Validation set of DRA-based signature

The abbreviations for tumor types were derived from the source data: A astrocytoma, AII astrocytoma grade II, AIII astrocytoma grade III, GBM glioblastoma, O oligodendroglioma, OII oligodendroglioma grade II, OIII oligodendroglioma grade III, OA oligoastrocytoma, OAII oligoastrocytoma grade II, OAIII oligoastrocytoma grade III, PA pilocytic astrocytoma

ISSN: 1752-0509